JPWO2022186311A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022186311A5 JPWO2022186311A5 JP2023503935A JP2023503935A JPWO2022186311A5 JP WO2022186311 A5 JPWO2022186311 A5 JP WO2022186311A5 JP 2023503935 A JP2023503935 A JP 2023503935A JP 2023503935 A JP2023503935 A JP 2023503935A JP WO2022186311 A5 JPWO2022186311 A5 JP WO2022186311A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- acid
- compound
- minutes
- atomic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021034026 | 2021-03-04 | ||
| JP2021146833 | 2021-09-09 | ||
| PCT/JP2022/009003 WO2022186311A1 (ja) | 2021-03-04 | 2022-03-02 | 化合物及び放射性標識化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022186311A1 JPWO2022186311A1 (cg-RX-API-DMAC7.html) | 2022-09-09 |
| JPWO2022186311A5 true JPWO2022186311A5 (cg-RX-API-DMAC7.html) | 2025-02-21 |
Family
ID=83155351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503935A Pending JPWO2022186311A1 (cg-RX-API-DMAC7.html) | 2021-03-04 | 2022-03-02 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240174622A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4303213A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022186311A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230154183A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022228911A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3210294A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202302542A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022186311A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4196175A4 (en) * | 2020-08-14 | 2025-07-30 | Clarity Pharmaceuticals Ltd | RADIOPHARMACEUTICAL COMPOUNDS, THEIR USES AND PROCESSES FOR THEIR PRODUCTION |
| CN116285684B (zh) * | 2023-05-15 | 2023-08-08 | 四川绚度眼视光科技有限公司 | 一种多功能超亲水涂层及其制备方法与应用 |
| CN116870176B (zh) * | 2023-08-03 | 2025-08-12 | 浙江大学 | PSMA靶向的PSMA-PARPi偶联物及制备方法和应用 |
| WO2025220711A1 (ja) * | 2024-04-17 | 2025-10-23 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物及びその製造方法、並びに放射性医薬組成物 |
| WO2026014283A1 (ja) * | 2024-07-09 | 2026-01-15 | 日本メジフィジックス株式会社 | 化合物、放射性標識化合物およびその製造方法、並びに放射性医薬組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| CA2760839C (en) | 2009-05-01 | 2019-02-12 | The Trustees Of The University Of Pennsylvania | Modified compstatin with peptide backbone and c-terminal modifications |
| CN108699108B (zh) | 2016-03-01 | 2022-04-08 | 国立大学法人千叶大学 | 放射性标记药物 |
| CN109982998A (zh) * | 2016-11-23 | 2019-07-05 | 癌靶技术有限责任公司 | 白蛋白结合psma抑制剂 |
| KR102724812B1 (ko) * | 2017-04-05 | 2024-11-01 | 코넬 유니버시티 | 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물 |
| CA3060143A1 (en) * | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
| CA3086454A1 (en) | 2017-09-26 | 2019-04-04 | National University Corporation Chiba University | Radioactive drug |
| AU2018352731B2 (en) | 2017-10-22 | 2023-10-05 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| KR102156385B1 (ko) * | 2018-03-30 | 2020-09-15 | (주)퓨쳐켐 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
| US12202908B2 (en) | 2018-05-17 | 2025-01-21 | Astellas Pharma Inc. | Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand |
| MX2021004146A (es) | 2018-10-10 | 2021-06-08 | Astellas Pharma Inc | Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado. |
| KR20210116437A (ko) * | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
| CA3118223A1 (en) * | 2018-12-18 | 2020-06-25 | Provincial Health Services Authority | Dual mode 18f-labelled theranostic compounds and uses thereof |
| MX2021008230A (es) | 2019-01-07 | 2021-08-11 | Astellas Pharma Inc | Conjugado que comprende ligando y fragmento fab de anticuerpo ceacam5. |
| MX2021013055A (es) * | 2019-04-26 | 2021-12-10 | Five Eleven Pharma Inc | Inhibidores de antigenos de membrana especificos de prostata (psma) como agentes diagnosticos y terapeuticos con radionuclidos. |
| TWI908773B (zh) * | 2020-03-04 | 2025-12-21 | 日商日本醫事物理股份有限公司 | 化合物及放射性標誌化合物 |
-
2022
- 2022-03-02 US US18/548,716 patent/US20240174622A1/en active Pending
- 2022-03-02 AU AU2022228911A patent/AU2022228911A1/en active Pending
- 2022-03-02 KR KR1020237029291A patent/KR20230154183A/ko active Pending
- 2022-03-02 JP JP2023503935A patent/JPWO2022186311A1/ja active Pending
- 2022-03-02 CA CA3210294A patent/CA3210294A1/en active Pending
- 2022-03-02 WO PCT/JP2022/009003 patent/WO2022186311A1/ja not_active Ceased
- 2022-03-02 EP EP22763364.1A patent/EP4303213A4/en active Pending
- 2022-03-03 TW TW111107807A patent/TW202302542A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019204121B2 (en) | Compositions, methods, and systems for the synthesis and use of imaging agents | |
| AU2008203856B8 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
| JP5290954B2 (ja) | スチリルピリジン誘導体及びアミロイド斑を結合させ画像化するためのその使用 | |
| AU2018279007A1 (en) | Compositions, methods, and systems for the synthesis and use of imaging agents | |
| AU2002323417A1 (en) | Stilbene derivatives and their use for binding and imaging amyloid plaques | |
| US11420910B2 (en) | Methods for low temperature fluorine-18 radiolabeling of biomolecules | |
| EP4303213A1 (en) | Compound and radioactive labeling compound | |
| AU2017307325B2 (en) | Diagnosis, treatment and prevention of neurotensin receptor-related conditions | |
| Procházková et al. | Lanthanide (III) complexes of monophosphinate/monophosphonate DOTA-analogues: effects of the substituents on the formation rate and radiolabelling yield | |
| AU2004210208B2 (en) | Diagnostic imaging agents with MMP inhibitory activity | |
| JPS5925397A (ja) | 心筋イメ−ジ剤および方法 | |
| EP1553985A2 (en) | Biphenyls and fluorenes as imaging agents in alzheimer's disease | |
| JPH06298779A (ja) | ヘテロ環イミノビスメチレンビスホスホン酸誘導体 | |
| JPWO1998027100A1 (ja) | 放射性遷移金属窒化物ヘテロ錯体 | |
| Gano et al. | Radiolanthanide complexes with tetraazamacrocycles bearing methylphosphonate pendant arms as bone seeking agents | |
| Southcott et al. | Bis (amido) bis (oxinate) diamine Ligands for theranostic radiometals | |
| US8940273B2 (en) | Tricarbonyl complexes with tridentate chelators for myocardium imaging | |
| CN101182333A (zh) | 一种99mTc标记的2-甲氧基苯基哌嗪类配合物及其制备方法和应用 | |
| Choi et al. | Synthesis and Physical Evaluation of^ 9^ 9^ mTc (CO)~ 3-labeled Cysteine-arylpiperazines for a Neuroreceptor (5-HT~ 1~ A) Imaging | |
| CN116940557A (zh) | 化合物及放射性标记化合物 | |
| HK1211571B (en) | Pyridazin-3(2h)-one derivatives as imaging agents for detecting myocardial perfusion |